Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES, February 27, 2026 /EINPresswire.com/ — ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Annexon, Inc. announced significant progress in its clinical development programs, particularly focusing on its lead investigational therapies aimed at treating classical complement-mediated ...